Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by FGL2 is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. Additionally we are shipping Fibrinogen-Like 2 Kits (37) and Fibrinogen-Like 2 Proteins (20) and many more products for this protein.
Showing 10 out of 93 products:
Human Monoclonal FGL2 Primary Antibody for IHC (p), IP - ABIN564725
OBrien, Morrison, Smith: Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor. in Biology of reproduction 2007
Show all 11 references for ABIN564725
Human Monoclonal FGL2 Primary Antibody for IHC (p), WB - ABIN2473615
Shalev, Liu, Koscik, Bartczak, Javadi, Wong, Maknojia, He, Liu, Diao, Winter, Manuel, McCarthy, Cattral, Gommerman, Clark, Phillips, Gorczynski, Zhang, Downey, Grant, Cybulsky, Levy: Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. in Journal of immunology (Baltimore, Md. : 1950) 2007
Mouse (Murine) Polyclonal FGL2 Primary Antibody for IHC, ELISA - ABIN1586047
Jia, Wang, Wang, Chen, Chen, Li, Long, Chen, Shu, Liu, Wang: TNF-α upregulates Fgl2 expression in rat myocardial ischemia/reperfusion injury. in Microcirculation (New York, N.Y. : 1994) 2013
these results suggest that FGL-2 mediates angiogenesis and tumorigenesis not by thrombin (show F2 Antibodies)-mediated mechanism but rather through FGF-2 (show FGF2 Antibodies)/ERK (show EPHB2 Antibodies) signaling pathway.
Results show that FGL2 functions as a key immune-suppressive modulator and has potential as an immunotherapeutic target for treating glioblastoma multiforme (GBM).
FGL-2 prothrombinase (show F10 Antibodies) activity in PBMC of lymphoma patients is increased in active disease and normalizes during remission, thus being a potential marker for follow up of lymphoma patients.
Studied fibrinogen-like protein 2 expression and its role in CRC (show CALR Antibodies) metastasis and underlying molecular mechanisms; results suggest that FGL2 plays an important oncogenic role in CRC (show CALR Antibodies) aggressiveness by inducing EMT (show ITK Antibodies).
The selected peptide sequence NPG (show OPA1 Antibodies)-12 may be a critical domain for hfgl2 prothrombinase (show F10 Antibodies) activity.
The proliferation index of CD8 (show CD8A Antibodies)(+)T cells after blocking FGL2 was higher.
immunomodulatory activity of FGL2 may be involved in the immunopathogenesis of inflammatory bowel disease
Circulating fibrinogen-like protein 2 is increased in patients with systemic sclerosis.
Serum fgl2 levels were increased among renal allograft recipients with acute rejection episodes to an extent dependent upon the pathological type and severity of the response.
FGL2 contributes to hepatocellular carcinoma tumour growth and angiogenesis in a thrombin (show F2 Antibodies)-dependent manner, and downregulation of its expression might be of therapeutic significance in HCC (show FAM126A Antibodies).
soluble FGL2 might be a potential renoprotective mediator involved in the renal self-repairing and remodeling.
studies of pig-to-baboon kidney xenografts undergoing acute vascular rejection in vivo revealed induction of pfgl2 expression on graft vascular endothelial cells.
FGL2 appears as one of the key players in immune regulatory processes favoring metacestode survival by promoting Regulatory T-cell activity and IL-17A (show IL17A Antibodies) production that contributes to FGL2-regulation.
TNF-alpha (show TNF Antibodies), and FGL2 form an integral network that contributes to coagulation and complement activation, and suggest that those are potential therapeutic targets in viral FH intervention.
these data strongly suggest that Treg cells expressing FGL2 mediate rapamycin-induced tolerance. Furthermore, a gene biomarker panel that includes fgl2 can distinguish between rejecting and tolerant grafts.
Mouse susceptibility to MHV-3-induced fulminant hepatitis may rely on C5a/C5aR interactions, for which ERK1/2 (show MAPK1/3 Antibodies) and p38 (show CRK Antibodies) pathways participate in up-regulating Fgl2 expression.
Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis.
Cysteines at positions 94, 97, 184 and 187, found in the coiled-coil domain were shown to be crucial for FGL2 oligomerization.
FGL2 binding to the FcgammaRIIB receptor expressed on sinusoidal endothelial cells (SECs) is a critical event in the initiation of the hepatic reperfusion injury cascade through induction of SEC and hepatocyte death.
The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis.
Fgl2 cleaves prothrombin (show F2 Antibodies) to thrombin (show F2 Antibodies) consistent with serine protease (show F2 Antibodies) activity and requires calcium, phospholipids, and factor Va for its full activity.
While membrane-bound Fgl2 acts as a prothrombinase, soluble Fgl2 is an immunomodulatory protein that has the ability to modulate T cell responses and to alter dendritic cell (DC) maturation to favor production of tolerogenic DC.
The protein encoded by this gene is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds. This protein may play a role in physiologic functions at mucosal sites.
, fibrinogen-like protein 2
, associated with MHV-3 induced prothrombinase activity
, cytotoxic T-lymphocyte-specific protein